Medpace (NASDAQ:MEDP) Receives Neutral Rating from Robert W. Baird

Robert W. Baird restated their neutral rating on shares of Medpace (NASDAQ:MEDP) in a research report report published on Wednesday morning, Marketbeat.com reports. Robert W. Baird currently has a $547.00 price objective on the stock, up from their prior price objective of $477.00.

A number of other analysts also recently issued reports on MEDP. Wall Street Zen downgraded shares of Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Jefferies Financial Group downgraded shares of Medpace from a “buy” rating to a “hold” rating and boosted their price objective for the stock from $490.00 to $515.00 in a research note on Tuesday. Royal Bank Of Canada dropped their price objective on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a research report on Friday, April 24th. Weiss Ratings reissued a “hold (c+)” rating on shares of Medpace in a research note on Thursday, July 2nd. Finally, BMO Capital Markets reduced their target price on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating on the stock in a report on Friday, April 24th. Two investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $469.17.

Medpace Trading Down 2.6%

MEDP stock opened at $531.99 on Wednesday. The company has a market cap of $15.19 billion, a PE ratio of 33.44, a price-to-earnings-growth ratio of 2.77 and a beta of 1.15. The stock has a 50-day moving average price of $462.24 and a two-hundred day moving average price of $495.96. Medpace has a 12-month low of $306.70 and a 12-month high of $628.92.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, topping analysts’ consensus estimates of $3.74 by $0.54. The company had revenue of $706.60 million for the quarter, compared to the consensus estimate of $697.82 million. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The company’s quarterly revenue was up 26.5% compared to the same quarter last year. During the same period last year, the business posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Equities analysts forecast that Medpace will post 17.04 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, General Counsel Stephen P. Ewald sold 16,349 shares of the firm’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the sale, the general counsel directly owned 20,343 shares in the company, valued at $9,154,350. This trade represents a 44.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 20.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. NewEdge Advisors LLC raised its position in shares of Medpace by 22.1% in the 1st quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock valued at $319,000 after purchasing an additional 190 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Medpace by 3.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock valued at $24,929,000 after acquiring an additional 3,010 shares during the last quarter. Geneos Wealth Management Inc. grew its holdings in Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after acquiring an additional 37 shares in the last quarter. Sivia Capital Partners LLC acquired a new position in Medpace during the 2nd quarter worth $296,000. Finally, M&T Bank Corp increased its position in shares of Medpace by 3.4% in the 2nd quarter. M&T Bank Corp now owns 939 shares of the company’s stock worth $295,000 after purchasing an additional 31 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.